Alnylam Pharmaceuticals
(ALNY)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -886,116 | -761,497 | -490,874 | -410,108 | -290,073 |
| Depreciation Amortization | 54,368 | 15,248 | 11,898 | 15,130 | 19,050 |
| Accounts receivable | -24,238 | 15,242 | -10,668 | -15,036 | 31,639 |
| Accounts payable and accrued liabilities | 92,354 | 74,835 | 26,629 | 10,098 | 1,676 |
| Other Working Capital | 402,381 | 45,099 | -2,902 | 17,219 | 35,116 |
| Other Operating Activity | 82,824 | 48,457 | 83,131 | 74,996 | 13,452 |
| Operating Cash Flow | $-278,427 | $-562,616 | $-382,786 | $-307,701 | $-189,140 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -300,521 | 414,657 | -306,152 | 357,148 | -306,900 |
| PPE Investments | -140,156 | -126,887 | -104,209 | -64,557 | -12,950 |
| Purchase Of Investment | N/A | -14,825 | 120,000 | -150,000 | N/A |
| Sale Of Investment | 30,000 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -7,000 | 0 | 0 | 0 | -1,471 |
| Investing Cash Flow | $-417,677 | $272,945 | $-290,361 | $142,591 | $-321,321 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 0 | N/A | N/A | 150,000 | 0 |
| Debt Repayment | N/A | 0 | -120,000 | N/A | N/A |
| Common Stock Issued | 853,184 | 65,470 | 1,244,891 | 28,428 | 616,555 |
| Common Stock Repurchased | N/A | N/A | N/A | -596 | -378 |
| Other Financing Activity | -30,000 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $823,184 | $65,470 | $1,124,891 | $177,832 | $616,177 |
| Exchange Rate Effect | -83 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 422,631 | 646,832 | 195,088 | 182,366 | 75,179 |
| End Cash Position | 549,628 | 422,631 | 646,832 | 195,088 | 180,895 |
| Net Cash Flow | $126,997 | $-224,201 | $451,744 | $12,722 | $105,716 |
| Free Cash Flow | |||||
| Operating Cash Flow | -278,427 | -562,616 | -382,786 | -307,701 | -189,140 |
| Capital Expenditure | -140,156 | -126,887 | -104,209 | -64,557 | -12,950 |
| Free Cash Flow | -418,583 | -689,503 | -486,995 | -372,258 | -202,090 |